Key Highlights
- Noetik closes $40M Series A funding round, led by Polaris Partners.
- Funds to expand Noetik’s spatial omics-based cancer atlas and CRISPR Perturb-Map platform.
- Polaris Partner Amy Schulman joins the board, with participation from new and existing investors.
Source: Business Wire
Notable Quotes
- “We are thrilled to have the support of incredible investors who share our vision of combining deep patient data and artificial intelligence to build the future of cancer therapeutics.” — Ron Alfa, M.D., Ph.D., CEO & Co-Founder at Noetik
- “We are excited to partner with Noetik and support their mission to build a pipeline of potentially transformative cancer programs.” — Amy Schulman, Managing Partner at Polaris Partners
- “The team’s speed of execution in building one of the most sophisticated AI-enabled oncology discovery engines in less than two years is unprecedented.” — James Hardiman, General Partner at DCVC
SoHC's Take
Noetik’s successful $40 million Series A round underscores the growing confidence in AI-driven approaches to drug discovery, particularly in the challenging field of oncology. The company’s innovative use of spatial omics data combined with self-supervised learning models positions it as a key player in the development of next-generation cancer therapies. With strong backing from both AI and biotech investors, Noetik is well-poised to make significant strides in precision oncology, potentially transforming how cancer is treated on a global scale. The addition of industry veterans like Amy Schulman and Shafique Virani further bolsters its potential for strategic growth and partnerships.
